Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Bristol-Myers (BMY) beats on earnings and sales in the fourth quarter on strength of Revlimid and Eliquis.

Bristol-Myers (BMY) Q4 Earnings Beat, 2021 EPS View Raised

Several of the drugs picked up in the 2019 acquisition of Celgene ranked among BMS' biggest growth drivers in Q4.

How Bristol Myers Squibb's Celgene Buyout Continued to Pay Off in Q4

Bristol Myers earnings and sales modestly topped Q4 views for the pharmaceutical company. BMY stock rose slightly early Thursday.

Bristol Myers Earnings Top Views; BMY Stock Rises Slightly

Bristol Myers (BMY) delivered earnings and revenue surprises of 6.57% and 4.43%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Bristol Myers Squibb (BMY) Q4 Earnings and Revenues Beat Estimates

Bristol Myers Squibb Co. said Thursday it had a net loss of $10.027 billion, or $4.45 a share, in the fourth quarter, wider than the loss of $1.056 billion, or 55 cents a share, posted in the year-earlier period, weighed down by charges relating to the MyoKardia asset acquisition, the purchase of Celgene, contingent value rights air value adjustments, equity investment gains, intangible assets impairment charges and other acquisition and integration expenses. Excluding those charges, the company had per-share earnings of $1.46, ahead of the $1.42 FactSet consensus.

Bristol Myers posts $10 billion loss as it books charges relating to MyoKardia and Celgene

Shares of Bristol-Myers Squibb (NYSE:BMY) rose 0.5% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 19.67% year over year to $1.46, which beat the estimate of $1.41.

Bristol-Myers Squibb: Q4 Earnings Insights

NEW YORK--(BUSINESS WIRE)--Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2020

Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2020

Amazon

AbbVie

Spotify

Amazon, Spotify, Bristol-Myers Squibb and AbbVie were our top stock trades for Thursday. Let's look at the charts of these earnings movers.

4 Top Stock Trades for Thursday: AMZN, SPOT, BMY, ABBV

Bristol Myers Squibb is scheduled to report its Q4 2020 results on Thursday, February 4. We expect the company to likely post revenue and earnings slightly below the consensus estimates, partly due to slowing sales growth rate of Opdivo.

What To Expect From Bristol Myers Squibb's Q4?

NEW YORK--(BUSINESS WIRE)--BMS & The Rockefeller University Announce License Agreement for SARS-CoV-2 Neutralizing Monoclonal Antibody Combination for the Treatment of COVID-19

Bristol Myers Squibb and The Rockefeller University Announce License Agreement for SARS-CoV-2 Neutralizing Monoclonal Antibody Combination for the Treatment of COVID-19

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--BMS Announces Positive Topline Results from Second Pivotal Phase 3 Psoriasis Study Showing Superiority of Deucravacitinib Compared to....

Bristol Myers Squibb Announces Positive Topline Results from Second Pivotal Phase 3 Psoriasis Study Showing Superiority of Deucravacitinib Compared to Placebo and Otezla® (apremilast)

NEW YORK & SHANGHAI--(BUSINESS WIRE)--WuXi STA to Purchase Bristol Myers Squibb Manufacturing Facility in Couvet, Switzerland

WuXi STA to Purchase Bristol Myers Squibb Manufacturing Facility in Couvet, Switzerland

Yamana Gold

Wells Fargo

3 Value Stocks That'll Make You Richer in February (and Beyond)

AstraZeneca

Gilead Sciences

Viatris

Merck

Pfizer

Covid-19 vaccines are getting all the glory after multi-bagger returns last year but these seven pharmaceutical stocks have a strong future ahead. The post 7 Pharmaceutical Stocks With Compelling Pipelines appeared first on InvestorPlace.

7 Pharmaceutical Stocks With Compelling Pipelines

Bristol Myers continues to de-risk the LOE on Revlimid mid-decade. The stock has been stuck around $60 for months while the biopharma continues growing EPS.

Bristol Myers Squibb: Out Of The Rut

The shares of Bristol-Myers Squibb Co (NYSE:BMY) are up 1.6% at $62.39 at last check, just ahead of the pharmaceutical name's fourth-quarter earnings, due out before the open on Thursday, Feb. 4.

BMY Flashing Bull Signal Ahead of Earnings

Investors will focus on regular top and bottom-line numbers along with key pipeline updates when Bristol-Myers (BMY) reports fourth-quarter 2020 results.

What's in the Cards for Bristol-Myers' (BMY) Q4 Earnings?

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--BMS Application for Zeposia (ozanimod) for the Treatment of Ulcerative Colitis Accepted for Filing with Priority Review by U.S. Food Administration

Bristol Myers Squibb Application for Zeposia® (ozanimod) for the Treatment of Ulcerative Colitis Accepted for Filing with Priority Review by U.S. Food and Drug Administration

Amgen

Biogen

Alexion Pharma

Regeneron Pharmaceuticals

Earnings season is in full swing, and we have put together a preview of some of the world's largest players in the health care sector reporting this coming week.

Amgen, Biogen, Gilead, Merck, Pfizer, and More Health Care Earnings Coming This Week

Eli Lilly

We think that Bristol Myers Squibb currently is a better pick compared to Eli Lilly & Company. BMY stock trades at about 3.7x trailing Revenues, compared to around 8.1x for LLY.

Bristol Myers Squibb Stock Can Offer Better Returns Over Eli Lilly

Bristol-Myers Squibb (BMY) closed the most recent trading day at $64.83, moving +0.42% from the previous trading session.

Bristol-Myers Squibb (BMY) Outpaces Stock Market Gains: What You Should Know

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--US FDA Approves OPDIVO in Combination with CABOMETYX as First-line Treatment for Patients with Advanced Renal Cell Carcinoma

U.S. Food and Drug Administration Approves OPDIVO® (nivolumab) in Combination with CABOMETYX® (cabozantinib) as First-line Treatment for Patients with Advanced Renal Cell Carcinoma

Bristol-Myers (BMY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Will Bristol-Myers (BMY) Beat Estimates Again in Its Next Earnings Report?

Pinterest

Both have the potential to drive solid returns in 2021.

2 Unstoppable Stocks to Buy With $1,000

Bristol Myers' (BMY) sBLA for the label expansion of Opdivo for gastric cancer, gastroesophageal junction cancer or esophageal adenocarcinoma gets priority review.

News for Bristol-Myers Stock (BMY)